bioAffinity Technologies, Inc. - What You Need to Know

Thinking about investing in bioAffinity Technologies? It is exciting to look at new biotech companies, but you need to cut through the jargon to understand what is happening under the hood. Here is the breakdown in plain English.

1. What does this company actually do?

bioAffinity focuses on early cancer detection. Their main product is a test called CyPath® Lung.

Instead of just looking for a tumor on a scan, their test analyzes cells in a patient’s mucus. They use a special dye that binds to cancer cells, making them "glow" under a microscope. By spotting these cells, the test helps doctors decide if a lung nodule is cancerous. This could help patients avoid invasive procedures like surgical biopsies.

2. What’s the latest news?

The company is currently focused on two fronts: growing sales and securing funding. Their primary operational goal is a planned clinical trial involving 3,200 patients across 22 Veterans Administration locations. The success of this trial is critical to proving that CyPath® Lung is a reliable diagnostic tool.

3. How do they make money and are they growing?

They are currently working to get more doctors and clinics to adopt CyPath® Lung.

The Reality Check: They generated about $9.4 million in revenue in 2024, up from $2.5 million in 2023. However, they are not yet profitable. In 2024, the company lost $9 million. Because their operating costs currently exceed their revenue, they rely heavily on outside funding to keep the lights on.

4. The "Going Concern" Warning

This is the most important part of their latest report. Their auditors issued a "going concern" warning. This means there is significant doubt about the company’s ability to stay in business. As of December 31, 2024, they had an accumulated loss of $53.6 million and only $1.1 million in cash. Management has acknowledged that without securing additional capital, they may run out of cash by April 2025.

5. How do they fund their operations?

Because they are not yet profitable, they raise money by selling shares, which impacts current investors:

• Dilution: To raise cash, the company issues new shares. This increases the total number of shares, which reduces your ownership percentage and can lower the value of your existing holdings.
• Complex Warrants: The company has issued warrants—contracts that allow holders to buy more shares at set prices. Exercising these warrants can lead to further dilution and creates complicated accounting liabilities on the balance sheet.

6. What are the main risks?

• Cash Burn: The company’s survival is tied to its ability to raise more money. If they fail to secure funding, they may be forced to cease operations.
• Clinical Trial Success: Their future hinges on the results of their 3,200-patient trial. If the results are poor, the product may fail to gain the market acceptance needed to become a standard of care.
• Regulatory Hurdles: The business operates under strict oversight from the FDA. If they lose their certifications or fail to obtain necessary clearances, they will be unable to sell their tests.

7. Who's running the company?

Maria Zannes serves as President and CEO. She is leading the company’s transition from a research-focused lab to a commercial business, overseeing the ongoing rollout of CyPath® Lung.

A final word of advice: Biotech stocks are inherently volatile. This company is in a high-risk phase where they are fighting for their financial life. The "going concern" warning is a major red flag that should be taken seriously. Only invest money you can afford to lose.

Disclaimer: I am an AI, not a financial advisor. Small-cap stocks are risky. Always read the company’s official SEC filings before making any investment decisions.